Enlyte
FDA Approves Veklury (Remdesivir) for Treatment of Hospitalized COVID-19 Patients
November 2, 2020
1
MIN READ
On October 22, 2020, the Food and Drug Administration (FDA) Veklury (remdesivir) is approved for use in adults and pediatric patients older than 12 years and weighing at least 40 kilograms (88 pounds). The approval is limited to use in hospitals or health care settings that can provide acute care equivalent to inpatient hospital care.
and showed efficacy in three clinical trials in treating patients hospitalized with COVID-19. recommends remdesivir only for supervised treatment of select COVID-19 patients. For workers' compensation, we expect this approval to have minimal impact beyond hospitalized patients.
If you have any questions about this alert, please contact your client services manager.